DermTech, a San Diego skin cancer diagnostics startup, seems to be making up for lost ground from a scrapped $25 million IPO: It just filed a $20 million equity fundraise with the SEC.
The company develops biopsy-free gene classifiers and and expression tests to screen for dermatologic conditions like melanoma. It gathers samples in a noninvasive manner – using an adhesive patch as opposed to a scalpel to collect skin cells.
DermTech analyzes the RNA extracted from these skin tissue samples to determine the expression levels of genes associated with melanoma – and make the diagnosis.
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The company, founded in 1995, withdrew its IPO filing last November. As of June 30, 2014 it had booked no revenue for that fiscal year.
[PHOTO: Flickr user Christiana Care]